Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis Patients treated with amlitelimab experienced up to 61.5% improvement in average Eczema Area and
Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
On the commercialization front, Teva will lead in Europe, Israel and specified countries while Sanofi will take the helm in North America, Japan, certain parts of Asia and the rest of the world.
Sitryx Therapeutics: Sitryx raises additional $39 million to progress development of disease-modifying therapeutics for chronic autoimmune and inflammatory disease finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.